Sampled Selected as Contractor for National Cancer Institute's Genomic Characterization Initiative

Sampled Selected as Contractor for NCI's Genomic Characterization Center

On March 26, 2025, Sampled, a leading integrated analytical biorepository and multiomics organization, proudly announced its designation as a Genomic Characterization Center by the National Cancer Institute (NCI). This recognition comes through a prestigious Indefinite Delivery, Indefinite Quantity (IDIQ) contract valued at up to $150 million, which empowers Sampled to play a vital role in the advancement of cancer research and genomic studies.

The NCI, a key segment of the National Institutes of Health, has engaged Sampled to provide support across four essential contract pools. Leveraging state-of-the-art technology, Sampled will deploy its expertise in delivering a range of genomic solutions that facilitate comprehensive understanding of cancer biology. This initiative is pivotal for researchers aiming to identify mutations, structural variations, and genetic abnormalities that contribute to tumor development and progression, thereby enhancing efforts in precision oncology.

Breakdown of Participation Across Contract Pools

Pool 1: DNA Sequencing

In the first pool, Sampled will conduct whole genome sequencing and whole exome sequencing utilizing DNA extracted from formalin-fixed paraffin-embedded (FFPE) or fresh frozen samples. This work will uncover critical mutations and genetic abnormalities facilitating targeted cancer studies to identify new therapeutic avenues and enhance large-scale cancer genomic research.

Pool 2: RNA Sequencing

The second segment encompasses RNA sequencing initiatives, enabling researchers to extract valuable insights through transcriptomic analysis. By utilizing RNA obtained from the same type of samples, Sampled will aid investigators in analyzing gene expression fluctuations and regulatory pathways, which are crucial for pinpointing potential biomarkers and understanding tumor microenvironment interactions.

Pool 3: Epigenome Characterization

The third pool focuses on epigenetic investigations, including methylation and chromatin accessibility characterization via advanced assay techniques. This aspect will assist NCI researchers in examining pivotal changes that signify cancer progression and treatment resistance, thereby igniting breakthroughs in therapeutic strategies.

Pool 4: Single Cell/Spatial Characterization

Finally, the fourth pool emphasizes single-cell and spatial characterization. Techniques such as single-cell RNA sequencing and ATAC-seq will be employed to dissect tumor heterogeneity and the intricate interplay within the tumor microenvironment. Such comprehensive analyses are expected to yield valuable insights into treatment resistance and bolster immunotherapy approaches that personalize cancer care protocols.

Leadership Comments

"Participation in the NCI Genome Characterization contract confirms Sampled's unwavering commitment to delivering innovative and trustworthy solutions for cancer research," stated Greg Morrissey, Senior Director of Government and Public Sector at Sampled. He emphasized the company's varied capabilities illustrated through engagement across all contract pools, supporting scientific endeavors aimed at unraveling cancer's complexities.

Furthermore, Chief Scientific Officer Shareef Nahas expressed, "This contract represents a significant milestone in our ongoing mission to assist cancer researchers with advanced multiomics tools. Our team's dedication to enhancing human health and medicine aligns perfectly with the NCI's objectives, allowing us to contribute meaningfully to the acceleration of novel cancer therapies and improved patient outcomes through extensive molecular insights."

Sampled’s Vision

Sampled stands as a trusted partner to the NCI and the broader research network, with its contributions poised to catalyze transformative discoveries in cancer genomics and epigenetics. By integrating cutting-edge technologies, robust infrastructure, and expert knowledge, Sampled ensures the timely availability of high-quality data and insights that researchers depend on.

About Sampled

Founded in 1999 as RUCDR Infinite Biologics at Rutgers University, Sampled has grown into a fully integrated laboratory and biorepository, featuring world-leading storage, sample management, multiomics, cellular services, and custom clinical kitting solutions. With operations in both the US and UK, Sampled adheres to CAP accreditation and CLIA licensing. The organization remains steadfast in its goal of providing unparalleled sample processing and analysis services, empowering researchers to uncover new frontiers in cancer research and advance human health.

For further details, please reach out to Caroline Mitchell, Director of Content & Creative Strategy at Sampled via email.